2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Tuesday, October 23, 2018

9:00AM-11:00AM: Abstract Number: 2582

Post-Marketing Safety of Secukinumab in Adult Patients with Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Cumulative Analysis across >96,000 Patient-Treatment Years Exposure

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2690

Potential Markers of Skin Involvement in Systemic Sclerosis

Systemic Sclerosis and Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 2129

Precipitating Anti-dsDNA Peptide Repertoires in Lupus

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2580

Predicting Treatment Persistence and Non-Persistence of Newly Initiated TNF Inhibitor Therapy in Ankylosing Spondylitis Patients: A Gender Comparison

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2195

Predictive Factors of a Positive PET/CT Scan for Vascular Involvement in Patients with Polymyalgia Rheumatica

Imaging of Rheumatic Diseases Poster III: Other Modalities

9:00AM-11:00AM: Abstract Number: 2572

Predictors for Use of Secukinumab 300mg over 150mg in Psoriatic Arthritis: A Meta-Analysis of Four Phase 3 Trials By Machine Learning

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2247

Predictors of End-Stage Renal Disease (ESRD) in Gout Patients and General Population (GP) Controls – a Role for Interstitial Nephritis, Urate Nephropathy?

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 2458

Predictors of Hypogammaglobulinemia during Rituximab Maintenance Therapy in Rheumatoid Arthritis: A 12-Year Longitudinal Multi-Center Study

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

9:00AM-11:00AM: Abstract Number: 2323

Predictors of Mortality in Patients with Hip Fragility Fracture

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2352

Predictors of Patient and Physician Perceptions of Gout Disease Activity

Patient Outcomes, Preferences, and Attitudes Poster II: Patient Perspectives

9:00AM-11:00AM: Abstract Number: 2324

Predictors of Refracture in Patients with Hip Fragility Fracture

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2499

Predictors of Rheumatoid Arthritis Development in Patients with Early Undifferentiated Arthritis: A 2-Years Follow-up Study

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

9:00AM-11:00AM: Abstract Number: 2621

Predictors of Survival of Adalimumab Treatment in the Management of Ankylosing Spondylitis and Psoriatic Arthritis in Canadian Routine Care

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2288

Preexisting Anti-Acetylcholine Receptor Autoantibodies and B Cell Lymphopenia Are Associated with the Development of Myositis in Thymoma Patients Treated with Avelumab, an Immune Checkpoint Inhibitor Targeting Programmed Death-Ligand 1

Muscle Biology, Myositis and Myopathies Poster III: Treatment and Classification Criteria

9:00AM-11:00AM: Abstract Number: 2704

Pregnancy in Systemic Sclerosis (SSc): A Systematic Review and Meta-Analysis

Systemic Sclerosis and Related Disorders – Clinical Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].